Table 2 Univariate analysis of overall survival

Age, y

≥54/<54

41/39

26/20

1.405

0.236

Gender

Male/Female

75/5

26/11

16.305

<0.001

RT

A-RT/C-RT/Non-RT

54/10/16

30/11/20

14.912

0.001

A-RT/C-RT

54/10

30/10

13.757

<0.001

A-RT/Non-RT

54/16

30/20

4.578

0.032

C-RT/Non-RT

10/16

11/20

1.197

0.274

BED

≥58.9 Gy/<58.9 Gy/0 Gy

≥58.9 Gy/<58.9 Gy

≥58.9 Gy/0 Gy

<58.9 Gy/0 Gy

42/22/16

42/22

42/16

22/16

42/19/20

42/19

42/20

19/20

5.763

3.890

4.740

0.048

0.016

0.049

0.029

0.827

Types

HBsAg

Child Pugh classification

I + II/III + IV

Negative/Positive

A/B

12 + 28/18 + 22

23/57

50/30

42/31/19/17

30/21

31/18

8.757

0.392

12.682

0.003

0.531

<0.001

PS (ECOG)

Concomitant disease

0–1/2–3

Yes/No

59/21

62/18

31/11

23/29

30.943

0.567

<0.001

0.451

Target therapy

Center location

Yes/No

Right/Left

30/50

60/20

24/23

23/21

0.202

0.223

0.653

0.637

diameter, cm

AFP, ng/L

≥5/<5

≤20/20 ~ 400/≥400

≤20/20 ~ 400

≤20/≥400

20 ~ 400/≥400

56/24

13/23/44

13/23

13/44

23/44

21/26

43/30/21

43/30

43/21

30/21

1.001

1.787

1.825

0.015

1.412

0.371

0.409

0.177

0.904

0.235

PLT, 10⁹/L

HGB, g/L

TBIL, μmol/L

Albumin, g/L

ALT, U/L

AST, U/L

≥100/<100

≥120/<120

≥20/<20

≥35/<35

≥50/<50

≥50/<50

54/26

51/29

34/46

30/50

30/50

46/34

26/20

26/21

20/31

22/24

20/26

20/29

0.258

0.019

4.263

0.115

1.777

0.010

0.611

0.891

0.039

0.735

0.182

0.975